您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Melanocyte stimulating hormone release inhibiting factor
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Melanocyte stimulating hormone release inhibiting factor
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Melanocyte stimulating hormone release inhibiting factor图片
CAS NO:2002-44-0
规格:98%
分子量:284.36
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍
MSH release-inhibiting factor
CAS:2002-44-0
分子式:C13H24N4O3
分子量:284.36
纯度:98%
存储:Store at -20°C

Background:

Melanocyte stimulating hormone release inhibiting factor,(C13H24N4O3), a tri-peptide with the sequence H2N-Pro-Leu-Gly-amide, MW= 284.35. Melanocyte-inhibiting factor (also known as Pro-Leu-Gly-NH2, Melanostatin, MSH release-inhibiting hormone or MIF-1) is an endogenous peptide fragment derived from cleavage of the hormone oxytocin, but having generally different actions in the body(1). MIF-1 produces multiple effects, both blocking the effects of opioid receptor activation(2), while at the same time acting as a positive allosteric modulator of the D2and D4dopamine receptor subtypes, as well as inhibiting release of other neuropeptides such as alpha-MSH, and potentiating melatonin activity(3). MIF-1 is unusually resistant to metabolism in the bloodstream, and crosses the blood–brain barrier easily, though it is poorly active orally and is usually injected.


A1121_1


Figure1?Formula of Melanocyte stimulating hormone release inhibiting factor


Ref:


1. Celis ME, Taleisnik S, Walter R (July 1971). "Regulation of formation and proposed structure of the factor inhibiting the release of melanocyte-stimulating hormone".Proceedings of the National Academy of Sciences of the United States of America68 (7): 1428–33.


2. Contreras PC, Takemori AE (June 1984). "Effect of prolyl-leucyl-glycinamide and alpha-melanocyte-stimulating hormone on levorphanol-induced analgesia, tolerance and dependence".Life Sciences34 (26): 2559–66.


3. Sandyk R (May 1990). "MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 inmovement disorders".The International Journal of Neuroscience52 (1-2): 59–65.